Eris Lifesciences Q4 Results
- BSE: 540596
- NSE: ERIS
- ISIN: INE406M01024
- Sector: Biotechnology & Drugs
BSE
1,467.15
1.85 (0.13%)
1.85 (0.13%)Volume586.00
Updated: Wed 11 Feb, 2026 | 15:27:09
NSE
1,469.203.80 (0.26%)
3.80 (0.26%)Volume64.82 K
Updated: Wed 11 Feb, 2026 | 15:41:05
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 25
Note: Comparison is on QoQ basis
Quarterly - Eris Lifesciences Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 24 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 530.75 | 558.34 | -4.94% | 456.39 | 16.29% |
| Depreciation/ Amortization | 77.84 | 81.20 | -4.14% | 53.90 | 44.41% |
| Operating Income | 174.55 | 169.11 | 3.22% | 94.53 | 84.65% |
| Net Income | 93.45 | 83.63 | 11.74% | 70.96 | 31.69% |
| Other Operating Expenses Total | 161.21 | 174.87 | -7.81% | 181.83 | -11.34% |
| Net Income Before Taxes | 128.28 | 116.16 | 10.43% | 76.65 | 67.36% |
| Total Revenue | 705.30 | 727.45 | -3.04% | 550.93 | 28.02% |
| Selling/ General/ Admin Expenses Total | 121.45 | 125.39 | -3.14% | 102.48 | 18.52% |
| Diluted Normalized EPS | 6.85 | 6.14 | 11.64% | 5.21 | 31.45% |